Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro

International Journal of Oncology

Volumn 30, Issue 1, 2007, Pages 193-200

  Festuccia, Claudio ^a   Muzi, Paola ^a   Gravina, Giovanni Luca ^b   Millimaggi, Danilo ^a   Speca, Silvia ^a   Dolo, Vincenza ^a   Ricevuto, Enrico ^a   Vicentini, Carlo ^b   Bologna, Mauro ^a,b  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

CEP 701; Neutrophin receptors; Prostate cancer chemotherapy

Indexed keywords

ANDROGEN RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBAZOLE DERIVATIVE; CEP 701; ENZYME INHIBITOR; INDOLE DERIVATIVE; NERVE GROWTH FACTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE A;

ARTICLE; CANCER INVASION; DRUG ANTAGONISM; GENETICS; HUMAN; MALE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

BRAIN-DERIVED NEUROTROPHIC FACTOR; CARBAZOLES; CELL LINE, TUMOR; ENZYME INHIBITORS; HUMANS; INDOLES; MALE; NEOPLASM INVASIVENESS; NERVE GROWTH FACTORS; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; RECEPTOR, TRKA; RECEPTORS, ANDROGEN;

EID: 34250378582     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.1.193     Document Type: Article

References (38)

1. Di Marco E, Mathor M, Bondanza S, Cutuli N, Marchisio PC, Cancedda R and De Luca M: Nerve growth factor binds to normal human keratinocytes through high and low affinity receptors and stimulates their growth by a novel autocrine loop. J Biol Chem 268: 22838-22846, 1993.
2. Djakiew D, Delsite R, Plufg B, Wrathall J, Lynch JH and Onoda M: Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate. Cancer Res 51: 3304-3310, 1991.
3. Otten U, Ehrhard P and Peck R: Nerve growth factor induces growth and differentiation of human B lymphocytes. Proc Natl Acad Sci USA 86: 10059-10063, 1989.
4. Rubin JB and Segal RA: Growth, survival and migration: the Trk to cancer (Review). Cancer Treat Res 115: 1-18, 2003.
5. Donovan MJ, Hempstead B, Huber LJ, Kaplan D, Tsoulfas P, Chao M, Parada L and Schofield D: Identification of the neurotrophin receptors p75 and trk in a series of Wilms' tumors. Am J Pathol 145: 792-801, 1994.
6. Oelmann E, Sreter L, Schuller I, Serve H, Koenigsmann M, Wiedenmann B, Oberberg D, Reufi B, Thiel E and Berdel WE: Nerve growth factor stimulates clonal growth of human lung cancer cell lines and a human glioblastoma cell line expressing high-affinity nerve growth factor binding sites involving tyrosine kinase signaling. Cancer Res 55: 2212-2219, 1995.
7. Miknyoczki SJ, Lang D, Huang L, Klein-Szanto AJP, Dionne CA and Ruggeri BA: Neurotrophin and trk receptors in human pancreatic ductal adenocarcinoma: expression patterns and effects on in vitro invasive behavior. Int J Cancer 81: 417-427, 1999.
8. McGregor LM, McCune BK, Graff JR, McDowell PR, Romans KE, Yancopoulos GD, Ball DW, Baylin SB and Nelkin BD: Role of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. Proc Natl Acad Sci USA 96: 4540-4545, 2001.
9. Davidson B, Reich R, Lazarovici P, Ann Florenes V, Nielsen S and Nesland JM: Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat 83: 119-128, 2004.
10. Deschryver-Kecskemeti K, Balogh K and Neet K: Nerve growth factor and the concept of neural-epithelial interactions. Arch Pathol Lab Med 111: 833-835, 1987.
11. Satoh F, Mimata H, Nomura T, Fujita Y, Shin T, Sakamoto S, Hamada Y and Nomura Y: Autocrine expression of neurotrophins and their receptors in prostate cancer. Int J Urol 8: S28-S34, 2001.
12. Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL, Murakata C, Djakiew D, Lamb J, Bova S, George D and Isaacs JT: Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res 4: 1887-1898, 1998.
13. Miknyoczki SJ, Wan W, Chang H, Dobrzanski P, Ruggeri BA, Dionne CA and Buchkovich K: The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice. Clin Cancer Res 8: 1924-1931, 2002.
14. Weeraratna AT, Dalrymple SL, Lamb JC, Denmeade SR, Miknyoczki S, Dionne CA and Isaacs JT: Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. Clin Cancer Res 7: 2237-2245, 2001.
15. Geldof AA, De Kleijn MAT, Rao BR and Newling DWW: Nerve growth factor stimulates in vitro invasive capacity of DU145 human prostatic cancer cells. J Cancer Res Clin Oncol 123: 107-112, 1997.
16. Angelsen A, Sandvik AK, Syversen U, Stridsberg M and Waldum HL: NGF-beta, NE-cells and prostatic cancer cell lines. A study of neuroendocrine expression in the human prostatic cancer cell lines DU-145, PC-3, LNCaP, and TSU-pr1 following stimulation of the nerve growth factor-beta. Scand J Urol Nephrol 32: 7-13, 1998.
17. Djakiew D, Pflug BR, Delsite R, Onoda M, Lynch J, Arand G and Thompson EW: Chemotaxis and chemokinesis of human prostate tumor cell lines in response to human prostate stromal cell secretory proteins containing a nerve growth factor like protein. Cancer Res 53: 1416-1420, 1993.
18. Van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ and Lucia MS: Molecular characterization of human prostate carcinoma cell lines. Prostate 57: 205-225, 2003. (Pubitemid 37267805)
19. Douma S, van Laar T, Zevenhoven J, Meuwissen R, van Garderen E and Peeper DS: Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430: 1034-1039, 2004.
20. Sinnappah-Kang ND, Kaiser AJ, Blust BE, Mrak RE and Marchetti D: Heparanase, TrkC and p75NTR: their functional involvement in human medulloblastoma cell invasion. Int J Oncol 27: 617-626, 2005.
21. George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J and Isaacs JT: Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res 59: 2395-2401, 1999.
22. Narayan P and Dahiya R: Establishment and characterization of a human primary prostatic adenocarcinoma cell line (ND-1). J Urol 148: 1600-1604, 1992.
23. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK and Sandberg AA: The LNCaP cell line - a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 37: 115-132, 1980.
24. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG and Kung HJ: Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 62: 6606-6614, 2002.
25. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF and Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1: 16-23, 1979.
26. Stone KR, Mickey DD, Wunderli H, Mickey GH and Paulson DF: Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21: 274-281, 1979.
27. Loop SM, Rozanski TA and Ostenson RC: Human primary prostate tumor cell line, ALVA-31: a new model for studying the hormonal regulation of prostate tumor cell growth. Prostate 22: 93-108, 1993.
28. Scaccianoce E, Festuccia C, Dondi D, Guerini V, Bologna M, Motta M and Poletti A: Characterization of prostate cancer DU145 cells expressing the recombinant androgen receptor. Oncol Res 14: 101-112, 2003.
29. Bonaccorsi L, Muratori M, Marchiani S, Forti G and Baldi E: The androgen receptor and prostate cancer invasion. Mol Cell Endocrinol 246: 157-162, 2006.
30. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ and Fidler IJ: Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 2: 1627-1636, 1996.
31. Angelucci A, Gravina GL, Rucci N, Festuccia C, Muzi P, Vicentini C, Teti A and Bologna M: Evaluation of metastatic potential in prostate carcinoma: an in vivo model. Int J Oncol 25: 1713-1720, 2004.
32. Dalal R and Djakiew D: Molecular characterization of neurotrophin expression and the corresponding tropomysin receptor kinases (trks) in epithelial and stromal cells of the human prostate. Mol Cell Endocrinol 134: 15-22, 1997.
33. Graham CW, Lynch JH and Djakiew D: Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. J Urol 147: 1444-1447, 1992.
34. Krygier S and Djakiew D: The neurotrophin receptor p75NTR is a tumor suppressor in human prostate cancer. Anticancer Res 21A: 3749-3755, 2001.
35. Krygier S and Djakiew D: Neurotrophin receptor p75(NTR) suppresses growth and nerve growth factor-mediated metastasis of human prostate cancer cells. Int J Cancer 98: 1-7, 2002.
36. Pflug B and Djakiew D: Expression of p75NTR in a human prostate epithelial tumor cell line reduces nerve growth factor-induced cell growth by activation of programmed cell death. Mol Carcinog 23: 106-114, 1998.
37. Guate JL, Fernandez N, Lanzas JM, Escaf S and Vega JA: Expression of p75(LNGFR) and Trk neurotrophin receptors in normal and neoplastic human prostate. BJU Int 84: 495-502, 1999.
38. Marshall JL, Kindler H, Deeken J, Bhargava P, Vogelzang NJ, Rizvi N, Luhtala T, Boylan S, Dordal M, Robertson P, Hawkins MJ and Ratain MJ: Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs 23: 31-37, 2005.